BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Cancer / Oncology

Pathos AI Completes Acquisition of Rain Oncology

Pathos AI, Inc. announced that it has, through its wholly owned subsidiary WK Merger Sub, Inc., successfully completed its tender offer to acquire all outs...

January 29, 2024 | News

Menarini Group and Insilico Medicine Ink Exclusive Deal for Novel KAT6 Inhibitor in Oncology, Including Breast Cancer Treatment

KAT6 is an emerging target in hormone sensitive breast tumors and other cancers. Overexpression of KAT6A/B correlates with poor clinical outcomes in...

January 05, 2024 | News

BioCity Doses First Patient in Phase Ib/II Trial of BC3402 Anti-TIM-3 mAb with IMFINZI for Advanced Hepatocellular Carcinoma

The study is being conducted at Zhongshan Hospital with Prof. Jia Fan as the principal investigator. Dr. Fan is a world-renowned liver cancer sur...

December 21, 2023 | News

Asia Pacific Oncology Alliance Report Emphasizes Patient Collaboration for Improved Cancer Care

Report highlights fundamental shift in treatment for cancer, from a terminal to a chronic disease that can be treated and managed Expl...

December 04, 2023 | News

Roche's Ying Ying Yeoh Explores the Power of Public-Private Partnerships in Shaping Healthcare's Future in Asia Pacific

Ying Ying Yeoh, a key figure at Roche, shares insights into the transformative impact of public-private partnerships (PPPs) on healthcare i...

November 29, 2023 | News

Pfizer and Astellas' XTANDI® Approved by U.S. FDA in Earlier Prostate Cancer Treatment Setting

Astellas Pharma Inc. announced that the companies received an approval by the U.S. Food and Drug Administration (FDA) of a supplemental New Drug Appl...

November 27, 2023 | News

Boehringer Ingelheim broadens immuno-oncology portfolio with T3 Pharma acquisition

Despite the significant transformation of the cancer treatment landscape by immunotherapies, long-term remissions only occur in 15-20% of cancer patients. ...

November 27, 2023 | News

Gilead and Kite Oncology Showcase Groundbreaking Analyses of Yescarta® CAR T-Cell Therapy

Gilead and Kite Oncology, announced that two poster presentations, covering results from two of the largest real-world analyses, will be presented during t...

November 03, 2023 | News

Bristol Myers Squibb Strengthens and Diversifies Oncology Portfolio With Acquisition of Mirati Therapeutics

Bristol Myers Squibb to Acquire Mirati for $58.00 Per Share, Representing $4.8 Billion Equity Value and Up to $5.8 Billion Including the Contingent Value R...

October 10, 2023 | News

Akeso and RemeGen Team Up for Gastric Cancer Therapy Study

On September 28, 2023, Akeso (9926.HK) announced that its subsidiary, Akeso Pharma, will collaborate with RemeGen (Yantai) Co., Ltd. (688331.SH/0...

October 02, 2023 | News

MediLink Therapeutics Focuses on Advancing ADCs for Cancer Treatment

On September 23, 2023, oncologists and experts from more than 60 clinical research centers across the country gathered in Guangzhou to ...

September 25, 2023 | News

Antengene Announces Phase I Study of Anti-CD24 Monoclonal Antibody ATG-031

Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading commercial-stage innovative, global biopharmaceutical company dedicated to disco...

September 22, 2023 | News

MGI Collaborates with National Cancer Centre Singapore for Asian Cancer Genomic Profiling

"We are excited to work with NCCS to uncover the unique molecular genomic composition of cancers prevalent in Asia by providing our DNBSEQ-G400 s...

September 18, 2023 | News

Samsung Biologics Expands Agreement with Bristol Myers Squibb to Manufacture Cancer Drug

Bristol Myers Squibb and Samsung Biologics have an existing manufacturing agreement for a commercial antibody cancer drug and have expanded the s...

September 18, 2023 | News

Stay Connected